Bruno Fionda

Dr. Bruno Fionda

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LTLuca Tagliaferri
Luca Tagliaferri
VLValentina Lancellotta
Valentina Lancellotta
BFBruno Fionda
Bruno Fionda
Monica MangoniMonica Mangoni
Monica Mangoni
CCCalogero Casà
Calogero Casà
VVVincenzo Valentini
Vincenzo Valentini
Melanoma is an extremely aggressive tumor and is considered to be an extremely immunogenic tumor because compared to other cancers it usually presents a well-expressed lymphoid infiltration. The aim of this paper is to perform a multidisciplinary comprehensive review of the evidence available about the combination of radiotherapy and immunotherapy for melanoma. Radiation, in fact, can increase tumor antigens visibility and promote priming of T cells but can also exert immunosuppressive action on tumor microenvironment. Combining radiotherapy with immunotherapy provides an opportunity to increase immunostimulatory potential of radiation. We therefore provide the latest clinical evidence about radiobiological rationale, radiotherapy techniques, timing, and role both in advanced and systemic disease (with a special focus on ocular melanoma and brain, liver, and bone metastases) with a particular attention also in geriatric patients. The combination of immunotherapy and radiotherapy seems to be a safe therapeutic option, supported by a clear biological rationale, even though the available data confirm that radiotherapy is employed more for metastatic than for non-metastatic disease. Such a combination shows promising results in terms of survival outcomes; however, further studies, hopefully prospective, are needed to confirm such evidence.

1 December 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DCDavide Cusumano
Davide Cusumano
JDJennifer Dhont
Jennifer Dhont
LBLuca Boldrini
Luca Boldrini
GCGiuditta Chiloiro
Giuditta Chiloiro
STStefania Teodoli
Stefania Teodoli
DVDirk Verellen
Dirk Verellen

5 September 2022 in Medicina
Verified
Journal Article
Open access
PDF file
FTFrancesco Tramacere
Francesco Tramacere
VLValentina Lancellotta
Valentina Lancellotta
Calogero CasàCalogero Casà
Calogero Casà
BFBruno Fionda
Bruno Fionda
PCPatrizia Cornacchione
Patrizia Cornacchione
LTLuca Tagliaferri
Luca Tagliaferri
Background and Objectives: Cervical cancer is a leading cause of mortality among women. Chemo-radiation followed by interventional radiotherapy (IRT) is the standard of care for stage IB–IVA FIGO. Several studies have shown that image-guided adaptive IRT resulted in excellent local and pelvic control, but it is associated with vaginal toxicity and intercourse problems. The purpose of this review is to evaluate the dysfunctions of the sexual sphere in patients with cervical cancer undergoing different cervix cancer treatments. Materials and Methods: We performed a comprehensive literature search using Pub med, Scopus and Cochrane to identify all the full articles evaluating the dysfunctions of the sexual sphere. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Results: One thousand three hundred fifty-six women included in five studies published from 2016 to 2022 were analyzed. The median age was 50 years (range 46–56 years). The median follow-up was 12 months (range 0–60). Cervical cancer diagnosis and treatment (radiotherapy, chemotherapy and surgery) negatively affected sexual intercourse. Sexual symptoms such as fibrosis, strictures, decreased elasticity and depth and mucosal atrophy promote sexual dysfunction by causing frigidity, lack of lubrication, arousal, orgasm and libido and dyspareunia. Conclusions: Physical, physiological and social factors all contribute to the modification of the sexual sphere. Cervical cancer survivors who were irradiated have lower sexual and vaginal function than the normal population. Although there are cures for reducing discomfort, effective communication about sexual dysfunctions following treatment is essential.

1 January 2018 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
LTLuca Tagliaferri
Luca Tagliaferri
ABAshwini Budrukkar
Ashwini Budrukkar
JLJACOPO LENKOWICZ
JACOPO LENKOWICZ
MCMauricio Cambeiro
Mauricio Cambeiro
FBFrancesco Bussu
Francesco Bussu
GKGyörgy Kovács
György Kovács
Purpose Clinical data collecting is expensive in terms of time and human resources. Data can be collected in different ways; therefore, performing multicentric research based on previously stored data is often difficult. The primary objective of the ENT COBRA (COnsortium for BRachytherapy data...

1 June 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
LTLuca Tagliaferri
Luca Tagliaferri
ASAlessandro Di Stefani
Alessandro Di Stefani
GSGiovanni Schinzari
Giovanni Schinzari
BFBruno Fionda
Bruno Fionda
ERErnesto Rossi
Ernesto Rossi
G(Gemelli Skin‐Cancer Multidisciplianry Tumour Board (S‐Mdtb)
Gemelli Skin‐Cancer Multidisciplianry Tumour Board (S‐Mdtb)
Linked articles: COVID‐19 SPECIAL FORUM. J Eur Acad Dermatol Venereol 2020; 34: e241–e255.

1 January 2020 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
PDF file
VLValentina Lancellotta
Valentina Lancellotta
JGJose Luis Guinot
Jose Luis Guinot
BFBruno Fionda
Bruno Fionda
ARAgata Rembielak
Agata Rembielak
ASAlessandro Di Stefani
Alessandro Di Stefani
LTLuca Tagliaferri
Luca Tagliaferri
Purpose The primary objective of the SKIN-COBRA (Consortium for Brachytherapy data Analysis) ontology is to define a specific terminological system to standardize data collection for non-melanoma skin cancer patients treated with brachytherapy (BT, interventional radiotherapy). Through...